Navigation Links
Pharma Industry Unites With Academia to Tackle Ongoing Problem
Date:10/28/2011

LONDON, October 28, 2011 /PRNewswire/ --

Leading academic and industry specialists to meet in Amsterdam next February to discuss the challenges that could see R&D grind to a halt and the newest ways to tackle them

Selecting and screening the correct polymorphs and ensuring the characterisation of the co-crystals in the most efficient and effective way has never been more vital. According to George Tranter from Chiralabs, "Crystallisation is one of the biggest problems of the pharmaceutical industry".

The 8th Annual Polymorphism and Crystallisation speaker panel will be dedicated to presenting the cutting edge technologies and techniques of getting the pharmaceutical product to the market whilst overcoming the problems of polymorphism.

According to an Engineer article "Co-crystallisation could speed up drug production" (5th September), scientists have started seeking to understand the science behind this process. However, co-crystallisation requires particular attention to considerations like availability and quality of drugs, waste streams generated and batch performance. Pharma IQ's Polymorphism and Crystallisation speakers will provide an insight into these issues live only on 28th and 29th February in Amsterdam. Case studies will be presented by the likes of Eli Lily, UCB Pharma and Novartis-MIT Centre for Continuous Manufacturing, and a fantastic interactive workshop will be run by an EPO representative.

Pharma IQ's summit will be dedicated to delivering cutting edge insights into areas such as:

  • Best timing and depth for a polymorphic screen during pharmaceutical development
  • Characterisation of co-crystals and selection of tools for correct characterisation tests
  • Polymorphic scale up
  • Application of PAT and QbD in pharmaceutical processes
  • Patenting of new polymorphs

At Polymorphism and Crystallisation, attendees will hear best practices from the big industry names like GlaxoSmithKline, Merck, AstraZeneca, Johnson and Johnson, Continuous Manufacturing and Crystallisation (CMAC), together with leading academic institutions like University of Loughborough, University of Leeds, University of Rouen, and more.

The full agenda, podcast, articles and interviews, are available on:
http://www.polyandcrys.com/PRNW/Event

The LinkedIn Group is open and welcomes anybody in topic and event related discussions:
http://www.linkedin.com/groups?home=&gid=1781786&trk=anet_ug_hm

Find the full program, event details and registration information on Polymorphism and Crystallisation 2012:
Visit: http://www.polyandcrys.com/PRNW/Event
Email enquire@iqpc.co.uk
Call: +44(0)207-368-9300

Media contact: Gergana Stoyanova
Tel: +44(0)2073689865
email: Gergana.Stoyanova@iqpc.co.uk
website: http://www.pharma-iq.com



'/>"/>
SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
2. Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance
3. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
4. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
5. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Expansion of Oncology Programs for Its Clients
6. Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate
7. Innovative Pharmacy Leader Jeanne Ann Stasny Joins Diplomat Specialty Pharmacy as Vice President of Pharmacy Services
8. Pharmaceutical Industry Leaders to Tackle Groundbreaking Challenges, Opportunities for Pharma & Biotech at Elite Event
9. Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals
10. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011
11. Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):